In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
Navigating the evolving landscape for psychedelic therapies
These substances may offer innovative treatment options for psychiatric conditions including PTSD, major and treatment-resistant depression, generalized...